Daniel Sulmasy to Risk Assessment
This is a "connection" page, showing publications Daniel Sulmasy has written about Risk Assessment.
Connection Strength
0.417
-
Perceptions of control and unrealistic optimism in early-phase cancer trials. J Med Ethics. 2018 02; 44(2):121-127.
Score: 0.077
-
Variations in Unrealistic Optimism Between Acceptors and Decliners of Early Phase Cancer Trials. J Empir Res Hum Res Ethics. 2017 10; 12(4):280-288.
Score: 0.077
-
Futility and the varieties of medical judgment. Theor Med. 1997 Mar-Jun; 18(1-2):63-78.
Score: 0.075
-
What research participants want to know about genetic research results: the impact of "genetic exceptionalism". J Empir Res Hum Res Ethics. 2011 Sep; 6(3):39-46.
Score: 0.051
-
Unrealistic optimism in early-phase oncology trials. IRB. 2011 Jan-Feb; 33(1):1-8.
Score: 0.049
-
Within you/without you: biotechnology, ontology, and ethics. J Gen Intern Med. 2008 Jan; 23 Suppl 1:69-72.
Score: 0.040
-
Dispositional optimism and therapeutic expectations in early-phase oncology trials. Cancer. 2016 Apr 15; 122(8):1238-46.
Score: 0.017
-
Patients' perceptions of the quality of informed consent for common medical procedures. J Clin Ethics. 1994; 5(3):189-94.
Score: 0.015
-
An exploration of relative health stock in advanced cancer patients. Med Decis Making. 2004 Nov-Dec; 24(6):614-24.
Score: 0.008
-
Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth. 2003; 24(4):329-44.
Score: 0.007